Inizio Ignite

Agilent Chooses Colorado for New Pharma Manufacturing Facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.
- Advertisement -

Agilent Technologies reports that it acquired 20 acres in Weld County in northern Colorado, on which it plans to build a pharmaceutical manufacturing facility.

“The products manufactured at this site will be used by our customers to improve the lives of patients suffering from a variety of diseases,” said Skip Thune, general manager of the company’s nucleic acids solutions division. “We are committed to meeting the ever-increasing needs of our customers for oligonucleotides.”

Researchers believe oligonucleotides hold the potential to treat various forms of cancer, diabetes, muscular dystrophy, and other disorders, according to Thune, who noted that the expansion would result in about 150 to 200 new jobs.

 

Latest stories

Related stories

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Nitrosamine Risk Mitigation in Global Pharma Manufacturing

Nitrosamine risk mitigation in global pharma manufacturing requires proactive control of chemical pathways, excipients, and operational practices to prevent trace-level carcinogenic impurities. Advanced analytics, rigorous risk assessments, and strengthened GMP frameworks are now essential to ensure long-term product safety and regulatory compliance.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »